Results 21 to 30 of about 29,136 (254)

Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine

Clinical & Translational Immunology, 2022
AbstractObjectiveDespite the high vaccine efficacy of mRNA COVID‐19 vaccines, there are individuals who developed excessive reactogenic and/or allergic responses after the first mRNA dose and were considered ineligible for further mRNA doses. CoronaVac, an inactivated SARS‐CoV‐2 vaccine, is recommended in Singapore as an alternative.MethodsIndividuals,
Yun Shan Goh, Siew‐Wai Fong, Angeline Rouers, Zi Wei Chang, Matthew Zirui Tay, Jean‐Marc Chavatte, Nicole Ziyi Zhuo, Pei Xiang Hor, Chiew Yee Loh, Yuling Huang, Joel Xu En Wong, Yong Jie Tan, Daniel Rui Xiang Lim, Bei Wang, Eve Zi Xian Ngoh, Siti Nazihah Mohd Salleh, Raphael Tze Chuen Lee, Surinder Pada, Louisa Jin Sun, Desmond Luan Seng Ong, Jyoti Somani, Eng Sing Lee, NCID Study Group, COVID‐19 Study Group, Sebastian Maurer‐Stroh, Cheng‐I Wang, Yee‐Sin Leo, Raymond TP Lin, Ee Chee Ren, David C Lye, Barnaby Edward Young, Poh Lian Lim, Lisa FP Ng, Laurent Renia   +33 more
openaire   +3 more sources

Self-reported adverse events after 2 doses of COVID-19 vaccine in Korea [PDF]

Epidemiology and Health, 2022
OBJECTIVES In Korea, a national coronavirus disease 2019 (COVID-19) vaccination program was implemented, including 4 vaccines against COVID-19. A text messaging-based survey, in addition to a passive adverse event reporting system, was launched to ...
Yunhyung Kwon, Insob Hwang, Mijeong Ko, Hyungjun Kim, Seontae Kim, Soon-Young Seo, Enhi Cho, Yeon-Kyeng Lee   +7 more
doaj   +1 more source

Harnessing the beneficial heterologous effects of vaccination [PDF]

Nature Reviews Immunology, 2016
Clinical evidence strongly suggests that certain live vaccines, in particular bacille Calmette-Guérin (BCG) and measles vaccines, can reduce all-cause mortality, most probably through protection against non-targeted pathogens in addition to the targeted pathogen. The underlying mechanisms are currently unknown.
Goodridge, H.S., Ahmed, S.S., Curtis, N., Kollmann, T.R., Levy, O., Netea, M.G., Pollard, A.J., Crevel, R. van, Wilson, C.B.   +8 more
openaire   +4 more sources

Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study

Human Vaccines & Immunotherapeutics, 2023
The global supply of COVID-19 vaccines has been limited, and concerns have arisen about vaccine supply chain disruptions in developing countries. Heterologous prime-boost vaccination, which involves using different vaccines for the first and second doses,
Kriangkrai Tawinprai, Pawornrath Jungsomsri, Onnicha Pinijnai, Fahsiri Tavonvunchai, Anchisa Lievjaroen, Paphada Suwannaroj, Taweegrit Siripongboonsitti, Thachanun Porntharukchareon, Gaidganok Sornsamdang, Teerapat Ungtrakul   +9 more
doaj   +1 more source

The impact of vaccines on heterologous adaptive immunity [PDF]

Clinical Microbiology and Infection, 2019
Vaccines induce antigen-specific memory in adaptive immune cells that enables long-lived protection against the target pathogen. In addition to this, several vaccines have beneficial effects greater than protection against their target pathogen. These non-specific effects are proposed to be the result of vaccine-induced immunomodulation. In the case of
N L, Messina, P, Zimmermann, N, Curtis
openaire   +2 more sources

The Effects of Heterologous Immunization with Prime-Boost COVID-19 Vaccination against SARS-CoV-2

Vaccines, 2021
Coronavirus Disease 2019 (COVID-19) pandemic, which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become the global challenge. Reaching global herd immunity will help end the COVID-19 pandemic.
Tzu-Chuan Ho, Yi-Ming Arthur Chen, Hung-Pin Chan, Chin-Chuan Chang, Kuo-Pin Chuang, Che-Hsin Lee, Cheng-Hui Yuan, Yu-Chang Tyan, Ming-Hui Yang   +8 more
doaj   +1 more source

Homologous and Heterologous Covid-19 Booster Vaccinations

New England Journal of Medicine, 2022
Although the three vaccines against coronavirus disease 2019 (Covid-19) that have received emergency use authorization in the United States are highly effective, breakthrough infections are occurring. Data are needed on the serial use of homologous boosters (same as the primary vaccine) and heterologous boosters (different from the primary vaccine) in ...
Robert L. Atmar, Kirsten E. Lyke, Meagan E. Deming, Lisa A. Jackson, Angela R. Branche, Hana M. El Sahly, Christina A. Rostad, Judith M. Martin, Christine Johnston, Richard E. Rupp, Mark J. Mulligan, Rebecca C. Brady, Robert W. Frenck, Martín Bäcker, Angelica C. Kottkamp, Tara M. Babu, Kumaravel Rajakumar, Srilatha Edupuganti, David Dobrzynski, Rhea N. Coler, Christine M. Posavad, Janet I. Archer, Sonja Crandon, Seema U. Nayak, Daniel Szydlo, Jillian A. Zemanek, Clara P. Dominguez Islas, Elizabeth R. Brown, Mehul S. Suthar, M. Juliana McElrath, Adrian B. McDermott, Sarah E. O’Connell, David C. Montefiori, Amanda Eaton, Kathleen M. Neuzil, David S. Stephens, Paul C. Roberts, John H. Beigel   +37 more
openaire   +2 more sources

Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil [PDF]

Nature Medicine, 2022
AbstractThere is considerable interest in the waning of effectiveness of coronavirus disease 2019 (COVID-19) vaccines and vaccine effectiveness (VE) of booster doses. Using linked national Brazilian databases, we undertook a test-negative design study involving almost 14 million people (~16 million tests) to estimate VE of CoronaVac over time and VE of
Cerqueira-Silva, T, Katikireddi, SV, de Araujo Oliveira, V, Flores-Ortiz, R, Júnior, JB, Paixão, ES, Robertson, C, Penna, GO, Werneck, GL, Barreto, ML, Pearce, N, Sheikh, A, Barral-Netto, M, Boaventura, VS   +13 more
openaire   +8 more sources

Homologous versus Heterologous prime-boost COVID-19 Vaccination in autologous hematopoietic stem cell transplantation recipients: a blinded randomized controlled trial

Frontiers in Immunology, 2023
Background/PurposeOptimizing vaccine efficacy is of particular concern in patients undergoing hematopoietic stem cell transplantation (HSCT), which mainly have an inadequate immune response to primary SARS-CoV-2 vaccination.
Leyla Sharifi Aliabadi, Manoochehr Karami, Manoochehr Karami, Maryam Barkhordar, Seyed Saeed Hashemi Nazari, Amir Kavousi, Mohammad Ahmadvand, Mohammad Vaezi, Mohammad Vaezi   +8 more
doaj   +1 more source

Vaccination and heterologous immunity: educating the immune system [PDF]

Transactions of The Royal Society of Tropical Medicine and Hygiene, 2015
This review discusses three inter-related topics: (1) the immaturity of the neonatal and infant immune response; (2) heterologous immunity, where prior infection history with unrelated pathogens alters disease outcome resulting in either enhanced protective immunity or increased immunopathology to new infections, and (3) epidemiological human vaccine ...
Gil, Anna, Kenney, Laurie L., Mishra, Rabinarayan, Watkin, Levi B., Aslan, Nuray, Selin, Liisa K.   +5 more
openaire   +3 more sources